TRAX

First Tracks Biotherapeutics Inc

36.63

Oct 12 • 8:00 AM ET +4.78 (15.00%)

Healthcare Biotechnology USA Small NASD

Today, 7:05 AMFirst Tracks Biotherapeutics reports positive Phase 1b ANB033 data in celiac disease showing statistically significant protection against gluten-induced damage and symptoms

Peers: VBIO LABT COAG ABVC AARD ABEO ABOS ACET SRXH AAPG

| Held by: VTI XBI IWM VXF IWO VTWO SCHA IWC VHT IWN

Scroll to Statements

Index	-
Market Cap	1.31B
Enterprise Value	1.15B
Income	-
Sales	-
Book/sh	4.77
Cash/sh	4.70
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Apr 06, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	7.68
P/C	7.79
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	14.28
Current Ratio	14.28
Debt/Eq	0.03
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-
EPS next Y	-3.64
EPS next Q	-0.90
EPS this Y	26.60%
EPS next Y	11.62%
EPS next 5Y	11.20%
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Aug 12 AMC
EPS/Sales Surpr.	-18.37% -

Insider Own	15.02%
Insider Trans	-0.73%
Inst Own	89.64%
Inst Trans	392.53%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	2.75%
SMA50	-9.04%
SMA200	24.15%
Trades

Shs Outstand	35.39M
Shs Float	30.36M
Short Float	17.10%
Short Ratio	7.01
Short Interest	5.19M
52W High	49.91 -26.62%
52W Low	14.72 148.82%
Volatility	8.23% 7.69%
ATR (14)	3.88
RSI (14)	51.38
Beta	-
Rel Volume	19.54
Avg Volume	740.19K
Volume	723,183

Perf Week	11.02%
Perf Month	0.51%
Perf Quarter	6.57%
Perf Half Y	54.22%
Perf YTD	83.13%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.08
Target Price	70.58
Prev Close	31.85
Price	36.63
Change %	15.00%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-30-26	Initiated	Canaccord Genuity	Buy	$50
Sep-18-26	Initiated	Evercore ISI	Outperform	$65
Sep-16-26	Initiated	Guggenheim	Buy	$100
Aug-18-26	Initiated	Wolfe Research	Outperform	$83
Jun-08-26	Initiated	Wells Fargo	Overweight	$30
May-04-26	Initiated	Piper Sandler	Overweight	$54
Apr-28-26	Initiated	H.C. Wainwright	Buy	$30
Apr-24-26	Initiated	Wedbush	Outperform	$30
Apr-24-26	Initiated	Leerink Partners	Outperform	$46
Apr-23-26	Initiated	JP Morgan	Overweight	$31
Apr-22-26	Initiated	Barclays	Overweight	$40
Apr-21-26	Initiated	UBS	Buy	$45

Show Previous Ratings

Today 07:00AM	First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease (GlobeNewswire) +15.00%
Oct-11-26 04:00PM	First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026 (GlobeNewswire)
Aug-26-26 04:15PM	First Tracks Biotherapeutics Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-12-26 04:15PM	First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Jul-10-26 12:14PM	TRAX Stock Hits All-Time High What's Driving The Super Rally? (Stocktwits) +11.85%
09:15AM	Loading…
Apr-20-26 09:15AM	First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases (GlobeNewswire) -17.37%

First Tracks Biotherapeutics, Inc. engages in the research and development of immunology therapeutics for autoimmune and inflammatory diseases. It focuses on clinical-stage programs for rosnilimab, ANB033 and ANB101. The company is headquartered in San Diego, CA.

CEOMr. Daniel R. Faga

Chief Medical OfficerDr. Paul F. Lizzul M.D.

Chief Financial OfficerMr. Ajim A. Tamboli C.F.A.

Chief Business OfficerMr. Benjamin Stone

SecretaryMr. Eric J. Loumeau

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Orwin John A	Director	Sep 15 '26	Option Exercise	0.00	1,300	0	17,995	Sep 17 04:05 PM
Ware J. Anthony	Director	Sep 02 '26	Option Exercise	5.74	39,265	225,381	54,925	Sep 04 04:25 PM
Ware J. Anthony	Director	Sep 02 '26	Sale	44.78	39,265	1,758,145	15,660	Sep 04 04:25 PM
JOE ANTHONY WARE	Director	Sep 02 '26	Proposed Sale	44.78	39,265	1,758,145		Sep 02 04:12 PM
Jain Rita	Director	Jun 15 '26	Option Exercise	0.00	7,330	0	19,194	Jun 17 04:05 PM
Schmid John P.	Director	Jun 15 '26	Option Exercise	0.00	6,030	0	37,652	Jun 17 04:05 PM
Orwin John A	Director	Jun 15 '26	Option Exercise	0.00	6,030	0	16,695	Jun 17 04:05 PM
Ware J. Anthony	Director	Jun 15 '26	Option Exercise	0.00	6,030	0	15,660	Jun 17 04:05 PM
Marquet Magda	Director	Jun 15 '26	Option Exercise	0.00	6,030	0	15,960	Jun 17 04:05 PM
FENTON DENNIS M	Director	Jun 15 '26	Option Exercise	0.00	6,030	0	10,995	Jun 17 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TRAX

First Tracks Biotherapeutics Inc

Upgrade your Finviz experience